681 related articles for article (PubMed ID: 28406713)
21. Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR.
Milla CE; Ratjen F; Marigowda G; Liu F; Waltz D; Rosenfeld M;
Am J Respir Crit Care Med; 2017 Apr; 195(7):912-920. PubMed ID: 27805836
[TBL] [Abstract][Full Text] [Related]
22. Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation.
Pohl K; Nichols DP; Taylor-Cousar JL; Saavedra MT; Strand MJ; Nick JA; Bratcher PE
PLoS One; 2018; 13(12):e0209026. PubMed ID: 30540818
[TBL] [Abstract][Full Text] [Related]
23. Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.
Deeks ED
Drugs; 2016 Aug; 76(12):1191-201. PubMed ID: 27394157
[TBL] [Abstract][Full Text] [Related]
24. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
Taylor-Cousar JL; Munck A; McKone EF; van der Ent CK; Moeller A; Simard C; Wang LT; Ingenito EP; McKee C; Lu Y; Lekstrom-Himes J; Elborn JS
N Engl J Med; 2017 Nov; 377(21):2013-2023. PubMed ID: 29099344
[TBL] [Abstract][Full Text] [Related]
25. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
Schneider EK; Reyes-Ortega F; Li J; Velkov T
Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis.
Cheng PC; Alexiou S; Rubenstein RC
Expert Rev Respir Med; 2019 May; 13(5):417-423. PubMed ID: 30929526
[TBL] [Abstract][Full Text] [Related]
28. Clinical effect of lumacaftor/ivacaftor in F508del homozygous CF patients with FEV
Aalbers BL; de Winter-de Groot KM; Arets HGM; Hofland RW; de Kiviet AC; van Oirschot-van de Ven MMM; Kruijswijk MA; Schotman S; Michel S; van der Ent CK; Heijerman HGM
J Cyst Fibros; 2020 Jul; 19(4):654-658. PubMed ID: 31924546
[TBL] [Abstract][Full Text] [Related]
29. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
[No Abstract] [Full Text] [Related]
30. Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment.
Ejiofor LCK; Mathiesen IHM; Jensen-Fangel S; Olesen HV; Skov M; Philipsen LKD; Pedersen CL; Pressler T
Pediatr Pulmonol; 2020 Dec; 55(12):3364-3370. PubMed ID: 32897653
[TBL] [Abstract][Full Text] [Related]
31. Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease.
Hubert D; Chiron R; Camara B; Grenet D; Prévotat A; Bassinet L; Dominique S; Rault G; Macey J; Honoré I; Kanaan R; Leroy S; Desmazes Dufeu N; Burgel PR
J Cyst Fibros; 2017 May; 16(3):388-391. PubMed ID: 28325531
[TBL] [Abstract][Full Text] [Related]
32. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.
Moheet A; Beisang D; Zhang L; Sagel SD; VanDalfsen JM; Heltshe SL; Frederick C; Mann M; Antos N; Billings J; Rowe SM; Moran A;
J Cyst Fibros; 2021 Mar; 20(2):333-338. PubMed ID: 32917547
[TBL] [Abstract][Full Text] [Related]
33. Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.
Hoppe JE; Chilvers M; Ratjen F; McNamara JJ; Owen CA; Tian S; Zahigian R; Cornell AG; McColley SA
Lancet Respir Med; 2021 Sep; 9(9):977-988. PubMed ID: 33965000
[TBL] [Abstract][Full Text] [Related]
34. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
[TBL] [Abstract][Full Text] [Related]
35. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor.
Singh SB; McLearn-Montz AJ; Milavetz F; Gates LK; Fox C; Murry LT; Sabus A; Porterfield HS; Fischer AJ
Pediatr Pulmonol; 2019 Aug; 54(8):1200-1208. PubMed ID: 31012285
[TBL] [Abstract][Full Text] [Related]
36. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
37. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
Rowe SM; Daines C; Ringshausen FC; Kerem E; Wilson J; Tullis E; Nair N; Simard C; Han L; Ingenito EP; McKee C; Lekstrom-Himes J; Davies JC
N Engl J Med; 2017 Nov; 377(21):2024-2035. PubMed ID: 29099333
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
Vadagam P; Kamal KM; Covvey JR; Giannetti V; Mukherjee K
J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102
[TBL] [Abstract][Full Text] [Related]
39. Tezacaftor and ivacaftor for the treatment of cystic fibrosis.
Paterson SL; Barry PJ; Horsley AR
Expert Rev Respir Med; 2020 Jan; 14(1):15-30. PubMed ID: 31626570
[No Abstract] [Full Text] [Related]
40. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
